Kornimate/medical-research-clean huggingface dataset:
meteorin-like levels in individuals with periodontitis

Conditions: Periodontitis; Gingivitis; Healthy

Summary: metrnl has proven to be an inflammatory-related immunoregulatory cytokine and shown to play a role in the pathogenesis of human inflammatory diseases. metrnl is highly expressed from the oral mucosa to the esophagus. periodontitis is a chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. the authors think that metrnl may play a role in the periodontitis. the aim of this study is to compare the metrnl, il-1β, and il-10 levels of healthy and periodontitis individuals.

periodontitis is a destructive chronic inflammatory disease that can start with localized inflammatory reactions created by the supporting tissues surrounding the teeth against microorganisms and then result in loss of teeth. cytokines play an important role in inflammation that occurs in periodontal disease. interleukine -1β ( il-1β ) levels are associated with periodontal destruction in the pathogenesis of periodontal disease. cytokines such as interleukine-10 (il-10) and transforming growth factor- β (tgf-β) have been reported to decrease periodontal disease progression rate. gingival crevicular fluid shows the cellular response in the periodontium. the most important host-related ingredients are inflammatory markers, including cytokines, enzymes, and interleukins. saliva analysis is used in the diagnosis of systemic conditions as well as in the diagnosis of oral pathologies. meteorin- like (metrnl) is a protein that plays a role in natural and acquired immune-related functions and inflammatory responses, and expressed in barrier tissues (skin and mucosa) as well as various macrophage populations, from dendritic cells and some granulocytes. metrnl has proven to be an inflammatory-related immunoregulatory cytokine and shown to play a role in the pathogenesis of human inflammatory diseases. metrnl, which is highly expressed from the oral mucosa to the esophagus, may play a role in the onset of periodontitis and an effective marker in preventing the progression of destruction. we think that metrnl plays an important role in periodontitis, an inflammatory disease. the aim of this study is to compare the metrnl, il-1β, and il-10 levels of healthy and periodontitis individuals

Eligibility criteria:
inclusion criteria: * systemically healthy * individuals who does not have a disease under treatment, * individuals without regular systemic medication exclusion criteria: * smoking * receiving periodontal treatment in the last 6 months * pregnancy * menopausal or menstrual period

Keywords: meteorin-like
effects of osteopathic visceral manipulation on the autonomic nervous system, balance and gastrointestinal disturbances in individuals with parkinson's disease

Conditions: Parkinson Disease

Summary: introduction: parkinson's disease (pd) is responsible for several changes in the body, such as balance, gastrointestinal and autonomic disorders and are associated with impairments in the clinical prognosis of these individuals. in this sense, therapies capable of minimizing this impact are extremely important. osteopathy has become an alternative treatment for individuals with neurological disorders and has been shown to be effective in treating various conditions, including pd. objective: a) to evaluate the acute effect of visceral manipulation directed to the intestines and visceral plexuses in the autonomic nervous system of pd patients; b) identify the effect of this approach, after four visits, on balance, plantar pressure, gastrointestinal disorders and autonomic nervous system in this population. materials and methods: for this randomized clinical trial, 28 adults diagnosed with pd will be recruited. subjects will be randomized to protocols in two groups: intervention protocol and placebo protocol, where both will consist of 4 visits twice a week. the intervention protocol will consist of osteopathic manipulative techniques and the sham protocol will consist of simulation of therapy, where the therapist will place his hands in the same regions of the intervention protocol, with superficial contact and without therapeutic intention in each region. the outcome measures of the study will consist of berg balance assessment and plantar pressure, rome survey on gastrointestinal disorders, and assessment of autonomic modulation by means of heart rate variability analysis. volunteers and evaluators will be blind to the protocol and not informed of their order. only the person responsible for the intervention will not be blind to the protocol. data will be analyzed according to normality (shapiro-wilk test), and comparisons of outcomes between the moments (pre and post) will be performed using the t-student test for paired data or wilcoxon, as normal and for comparisons between protocols. placebo and intervention, student's t-test for unpaired data or mann-whitney test according to normality will be applied. the adopted statistical significance will be fixed at 5%.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's; * not having cardiorespiratory diseases; * not being a smoker; * do not use alcoholic beverages; * no cognitive deficit; * no osteoarticular deformities, plantar ulcers, total or partial amputation of the feet; * they do not need auxiliary devices for walking exclusion criteria: * data from individuals with a series of heart rate intervals with less than 95% of sinus beats will be excluded from the study.

Keywords: parkinson
multicenter selective lymphadenectomy trial (mslt)

Conditions: Melanoma

Summary: subjects must be diagnosed with melanoma. all subjects receive wide excision (wex) of their melanoma. if the melanoma meets study requirements, the subject is randomized to receive either (1) no further surgical procedures as part of the study or (2) a selective lymphadenectomy with the possibility of a complete lymphadenectomy. subjects are then followed for 10 years.


Eligibility criteria:
inclusion criteria: 1. the patient consents to be in the study. 2. the patient must have invasive melanoma with: 1) clark level iii and breslow thickness greater than or equal to 1.00 mm; or 2) clark level iv or v with any breslow thickness. a confirmation of diagnosis and thickness must be made by the institutional pathologist. 3. the primary cutaneous melanoma site must be on the head, neck, trunk, extremity, scalp, palm of the hand, sole of the foot, or subungual skin. 4. the patient's biopsy must have been completed no more than 10 weeks before the initial visit to the clinic. (surgery must be scheduled within three months of the biopsy.) 5. the patient must be between 18 and 75 years old. 6. the patient must have a life expectancy of at least 10 years from the time of diagnosis, excluding the diagnosis of melanoma. exclusion criteria: 1. the patient had a prior wide excision of the primary with a diameter of excision greater than or equal to 3.0 cm and the shortest margin from the tumor edge to the excision edge was measured by a pathologist to be greater than or equal to 1.5 cm; or the patient had an elliptical excision and a margin beyond the tumor edge was greater than or equal to 1.5 cm at the narrowest margin. 2. the primary cutaneous melanoma involves the eye, ear, mucous membranes. 3. the patient has clinical evidence of satellite lesions, in-transit, regional nodal or distant metastases. 4. the patient has a second primary invasive melanoma. 5. the patient has had any type of solid tumor or hematologic malignancy during the past 5 years. exceptions are if the patient has been treated for t1 lesions (e.g., squamous cell carcinoma of the skin, basal cell carcinoma or in situ carcinoma of the uterine cervix) during the past 5 years, but has not received treatment within the last 6 months. 6. the patient has had prior skin grafts, tissue transfers or flaps, or lymph node dissections that may alter the lymphatic drainage pattern from a primary cutaneous melanoma to the adjacent regional lymph node basins. 7. the patient has had previous chemotherapy, immunotherapy or radiation therapy. 8. the patient has had an organ transplantation and is receiving immunosuppressive agents as a result of the transplantation. 9. the patient has taken oral or parenteral steroids or immunosuppressive drugs within the last 6 months. 10. the patient has any known primary or secondary immune deficiencies. 11. the patient has another medical condition that will affect life expectancy. 12. the patient is pregnant. 13. evidence that the patient cannot undergo selective lymph node dissection for any reason.

Keywords: slnd sentinel melanoma surgical
effect of inhaled hydroxy gas on long covid symptoms

Conditions: Post-Acute COVID-19 Syndrome

Summary: the goal of this clinical trial is to see if several weeks of self-administered, home-based, treatment involving breathing hydroxy gas (a mixture of hydrogen and oxygen) for at least 2 hours a day for 3 weeks, will relieve symptoms in patients suffering from long covid. the main question it aims to answer is whether inhaling hydroxy gas might be a useful treatment option to help patients with long covid cope better and recover quicker from this condition. participants will wear a nasal canula (placed in their nostrils) to inhale a gas from a machine that they will be trained to use at home. in one 3-week period, the machine will deliver hydroxy gas (treatment) and in a separate 3-week period the machine will deliver normal air (placebo). the order of the treatment or placebo periods will be randomized and separated by a minimum of 3-weeks during which the participants will not use the machine ('washout' period). neither the participant nor the investigators will know which 3-week period is the treatment and which is the placebo phase. participants will visit the laboratory (or be tested at home) at the start and end of each 3-week period. testing will involve measuring physical ability (handgrip strength, how far they can walk in 6 minutes, how many times they can stand up and sit down in a minute), breathing problems (how hard they can blow out, how breathless they feel), cognitive ability (how quickly they can mark out a trail based on numbers and letters), and state of mind (mood). the investigators hypothesize that compared to inhaling placebo, inhaling the hydroxy gas will produce greater improvement in physical ability, relieve breathing problems, and enhance cognitive ability and mood, thereby showing that it can relieve key symptoms of long covid


Eligibility criteria:
inclusion criteria: * any moderate or severe pain, breathlessness, or fatigue associated with long covid * live within an hour's drive of the oxford brookes campus exclusion criteria: * pre-existing secondary diseases; tumors, mental health conditions, chronic respiratory conditions such as chronic obstructive pulmonary disease (copd), and cardiac disease * previous requirement of icu treatment due to covid * acute or chronic infections or no pre-existing autoimmune diseases

Keywords: post-acute covid-19 syndrome long covid long haul covid-19 long-haul covid post-acute sequelae of covid infection
colchicine on-admission to reduce inflammation in acute coronary syndrome (color-acs)

Conditions: Non ST Segment Elevation Acute Coronary Syndrome

Summary: since colchicine is known to have anti-inflammatory effects and inflammation is an early component of acute coronary syndrome (acs), this study aims to evaluate the acute effects of low-dose colchicine, in addition to atorvastatin, administered on-admission to statin-naive patients with non-st elevation acs scheduled for early invasive strategy.

on-admission all statin naive nsteacs patients are randomized to receive either standard treatment of atorvastatin 80 mg or standard treatment plus colchicine (1 mg loading dose followed by 0.5 mg/day). inflammatory biomarker high sensitivity c reactive protein (hs-crp) is measured in all patients on-admission and every 24 hours thereafter until discharge. cardiac and renal function parameters are evaluated to evidence the possible beneficial effects of the administration of colchicine in addition to atorvastatin alone both short- and medium-term (up to 30 days). colchicine tolerance is also investigated through monitoring for clinical side effects.

Eligibility criteria:
inclusion criteria: * non-st elevation acute coronary syndrome; * ≥ 18 years; * statin-naive. exclusion criteria: * prior statin therapy and/or colchicine treatment; * known allergy or hypersensitivity to colchicine or statins; * current treatment with potent inhibitors of cyp3a4 or p-glycoprotein (eg., cyclosporin, antiretroviral drugs, antimycotics, erythromicin and clarythromycin); * previous or scheduled administration of any immunosuppressive therapy; * known active malignancy; * severe kidney disease (creatinine \> 3 mg/dl or dialysis) * severe liver disease (alt and/or ast, \> double ref. normal values in case of (a) total bilirubin \> double ref. normal values, or (b) alteration in coagulation (inr\> 1,5); * severe heart failure (nyha class ≥ 3 or cardiogenic shock) at hospital presentation; * severe acute or chronic gastro-intestinal disease (nausea, vomiting, diarrhea, malabsorption disease, malnutrition); * pregnancy or lactation; * current covid-19 or other infectious disease; * refusal of consent.

Keywords: colchicine atorvastatin acute coronary syndrome c reactive protein acute kidney injury
infusion of specially treated umbilical cord stem cells after chemoradiation treatment for blood cancers

Conditions: Acute Lymphocytic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome; Non-Hodgkin Lymphoma; Chronic Myelogenous Leukemia

Summary: this study hopes to show that specially treated umbilical cord cells, called stem cells, can be safely given to a person after they receive chemoradiation therapy or chemotherapy for their illness. during chemoradiation therapy or chemotherapy, a person loses all of the cells that are needed to make the different types of cells in their blood, including their immune system cells. these cells must be replaced in order for the blood and immune systems to work properly. some people receive bone marrow transplants or other types of stem cell transplants to get the cells they need. cb001 is being developed as an option for people who need bone marrow transplants or other types of transplants to replace those cells. it is also being developed for people who do not have the option of other types of transplants.


Eligibility criteria:
inclusion criteria: * do not have identical or 5/6 related matched bone marrow, peripheral blood or umbilical cord * stable disease and lack of unrelated donor * acute myeloid leukemia (aml) in 2nd or subsequent complete remission or first remission with high risk features * all in 2nd or subsequent remission or first remission with high risk features * myelodysplastic syndrome (mds) * non-hodgkin lymphoma (nhl) * chronic myelogenous leukemia (cml) * adequate function of heart, liver, kidneys and lungs exclusion criteria: * females who are pregnant * poor ability to perform daily activities * weight under 40 kilograms (88 pounds) * aml caused by chemoradiation * prior stem cell transplant * uncontrolled infection at time of transplant * active fungal infection * hiv infection * primary myelofibrosis * receiving other research drugs * unable to provide informed consent

Keywords: umbilical cord blood transplant all aml mds nhl cml
study evaluating predictors of response in patients with ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: the objective of this observational study is to determine the incidence of response in patients with predictive factors of major clinical response in active ankylosing spondylitis (as) in patients who start anti-tumor necrosis factor (anti-tnf) therapy and correlate these findings in patients who switch from one to another anti-tnf due to inefficacy under usual clinical practice conditions in spain.

a sample size of 240 patients, 120 of them exposed and 120 not exposed to factors of response. sample will be obtain from all the consecutive patients attending the rheumatology settings included in the study who fulfill the inclusion criteria

Eligibility criteria:
inclusion criteria: * patients diagnosed of active as who will start anti-tnf therapy following standard clinical practice as per summary of product characteristics doses. * \>18 years, both genders, any disease duration * signature of informed consent exclusion criteria: * previous treatment with biological therapies * active tuberculosis infection (local guidelines for appropriate screening and treatment of tuberculosis in the setting of anti-tnf therapy must be followed)

Keywords: ankylosing spondylitis;predictive factors
act-ed: accessibility and feasibility of an acceptance and commitment therapy (act)-based eating disorder prevention program

Conditions: Eating Disorders Symptoms; Eating Pathology; Disordered Eating Behaviors

Summary: the goal of this clinical trial is to investigate the accessibility and feasibility of an online group prevention program developed for women at risk for eating disorders. also, to conduct a preliminary analysis of treatment efficacy. the main questions it aims to answer are: does act-ed an acceptable intervention for women at risk for eating disorders? does intervention result in reduced eating pathology? participants will: join the online, 4-session act-based group program fill the measures at pre-test, post-test and follow-up assessment


Eligibility criteria:
inclusion criteria: * being a woman aged 18 years or older * exhibiting disordered eating behaviors (ede-q score ≥ 3.03) * experiencing body dissatisfaction (bsq-34 score ≥ 110) exclusion criteria: * current or past diagnosis/treatment for an eating disorder * currently receiving psychotherapy * currently receiving psychiatric medication (not excluded if there has been no change in treatment in the last 6 months) * having chronic psychiatric disorders (e.g. psychosis) * having a substance addiction

Keywords: disordered eating eating pathology prevention eating disorders early intervention
risedronate for the prevention of osteoporosis in people with spinal cord injury.

Conditions: Acute Spinal Cord Injury.

Summary: the purpose of this study is to find out if risedronate works to prevent osteoporosis after spinal cord injury.


Eligibility criteria:
inclusion criteria: * traumatic spinal cord injury less than 100 days. * must be able to swallow tablets and sit upright. exclusion criteria: * bilateral knee flexion contractures. * pregnant, lactating or post-menopausal females. * paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis. * treatment in the last year with calcitonin, fluoride or anabolic steroid. * concurrent treatment with prednisone.

Keywords: osteoporosis spinal cord injury
oxidation rates of the different substrates during exercise in children and adolescents with juvenile idiopathic arthritis. case-control study and cases treated / cases not treated with anti-tnfα

Conditions: Juvenile Idiopathic Arthritis

Summary: during exercise, energy comes mainly from carbohydrates and lipids. the relative contribution of lipids and glucose as energy substrates to exercise depends on the parameters of the exercise (duration, intensity and level of training) and the physiological conditions of the subject. inflammatory diseases such as juvenile idiopathic arthritis (jia) are treated, for the most severe forms, by biotherapies. these treatments target certain pro-inflammatory cytokines including tnfα. in adults with rheumatoid arthritis several studies have shown that treatment with anti-tnfα increases insulin sensitivity. there is no data on the oxidation of energy substrates during exercise in children and adolescents with aji, nor on the impact of anti-tnfα treatments on the oxidation of energetic substrates in children. investigators hypothesize that, compared to healthy children, children with jia should exhibit altered oxidation of energy substrates at rest and submaximal physical exercise due to physical deconditioning and inflammation. in addition, those treated with anti-tnfα should have an oxidation profile of energy substrates at exercise different from that of patients not treated with anti-tnfα. investigators also hypothesize that anti-tnfα treatments modify the contribution of energy chains (aerobic, anaerobic and anaerobic alactic) during the exercise.

annual evaluation by lipoxmax test and wingate anaerobic test (want) during 3 years or until the transition from pediatric to adult care. for healthy volunteer, only one lipaxmax and wingate test.

Eligibility criteria:
inclusion criteria: * children with juvenile idiopathic arthritis exclusion criteria: * active infection * bmi \> 25 * systemic corticosteroid within last 3 months

Keywords: juvenile idiopathic arthritis fat oxidation exercise
reducing anticholinergic bladder medication use in spinal cord injury with home neuromodulation

Conditions: Chronic Spinal Cord Injury; Neurogenic Bladder

Summary: the purpose of this study is to determine the efficacy of home transcutaneous tibial nerve stimulation (ttns) in spinal cord injury(sci) and to determine the impact on quality of life using ttns at home


Eligibility criteria:
inclusion criteria: * traumatic and non-traumatic sci performing ic * up to 2 anticholinergic overactive bladder (oab) medications * no changes in oab medications * neurologic level of injury above t10 * english and spanish speaking exclusion criteria: * past history of genitourinary diagnoses or surgeries * history of central nervous system (cns) disorders and/or peripheral neuropathy * pregnancy * lower motor neuron bladder * concern for tibial nerve pathway injury * absence of toe flexion or ad with electric stimulation * bladder chemodenervation in past 6 months * potential for progressive sci including neurodegenerative sci, als, cancer myelopathy, multiple sclerosis, transverse myelitis

Keywords: electric stimulation